Correction to: A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial

Affiliations

¹ University Hospitals Leuven (UZ Leuven), Leuven, Belgium. timothy.devos@uzleuven.be.
² Catholic University of Leuven (KU Leuven), Leuven, Belgium. timothy.devos@uzleuven.be.
³ University Hospitals Leuven (UZ Leuven), Leuven, Belgium.
⁴ Catholic University of Leuven (KU Leuven), Leuven, Belgium.
⁵ Universitair Ziekenhuis Gent, Ghent, Belgium.
⁶ Instituut voor Tropische Geneeskunde, Antwerp, Belgium.
⁷ Sciensano, Elsene, Belgium.
⁸ Rode Kruis Vlaanderen, Mechelen, Belgium.
⁹ Universite Libre de Bruxelles Institut d 'Immunologie Medicale, Bruxelles, Belgium.
¹⁰ Universite de Liege, Liege, Belgium.
¹¹ Universite Libre de Bruxelles, Bruxelles, Belgium.
¹² Leuven Coordinating Centre, Leuven, Belgium.
¹³ Katholieke Universiteit Leuven Rega Institute for Medical Research, Leuven, Belgium.
¹⁴ Universitair Ziekenhuis Brussel, Bruxelles, Belgium.
¹⁵ Croix Rouge de Belgique, Bruxelles, Belgium.
¹⁶ Interuniversity Institute for Biostatistics and statistical Bioinformatics, Leuven, Belgium.
¹⁷ Universitair Ziekenhuis Antwerpen, Antwerpen, Belgium.
¹⁸ Cliniques Universitaires Saint-Luc, Sint-Lambrechts-Woluwe, Belgium.

Published Erratum

Timothy Devos et al. Trials. 2020.

. 2020 Dec 14;21(1):1024.

doi: 10.1186/s13063-020-04947-2.

¹ University Hospitals Leuven (UZ Leuven), Leuven, Belgium. timothy.devos@uzleuven.be.
² Catholic University of Leuven (KU Leuven), Leuven, Belgium. timothy.devos@uzleuven.be.
³ University Hospitals Leuven (UZ Leuven), Leuven, Belgium.
⁴ Catholic University of Leuven (KU Leuven), Leuven, Belgium.
⁵ Universitair Ziekenhuis Gent, Ghent, Belgium.
⁶ Instituut voor Tropische Geneeskunde, Antwerp, Belgium.
⁷ Sciensano, Elsene, Belgium.
⁸ Rode Kruis Vlaanderen, Mechelen, Belgium.
⁹ Universite Libre de Bruxelles Institut d 'Immunologie Medicale, Bruxelles, Belgium.
¹⁰ Universite de Liege, Liege, Belgium.
¹¹ Universite Libre de Bruxelles, Bruxelles, Belgium.
¹² Leuven Coordinating Centre, Leuven, Belgium.
¹³ Katholieke Universiteit Leuven Rega Institute for Medical Research, Leuven, Belgium.
¹⁴ Universitair Ziekenhuis Brussel, Bruxelles, Belgium.
¹⁵ Croix Rouge de Belgique, Bruxelles, Belgium.
¹⁶ Interuniversity Institute for Biostatistics and statistical Bioinformatics, Leuven, Belgium.
¹⁷ Universitair Ziekenhuis Antwerpen, Antwerpen, Belgium.
¹⁸ Cliniques Universitaires Saint-Luc, Sint-Lambrechts-Woluwe, Belgium.

No abstract available

Erratum for

A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial.
Devos T, Geukens T, Schauwvlieghe A, Ariën KK, Barbezange C, Cleeren M, Compernolle V, Dauby N, Desmecht D, Grimaldi D, Lambrecht BN, Luyten A, Maes P, Moutschen M, Romano M, Seyler L, Nevessignsky MT, Vandenberghe K, van Griensven J, Verbeke G, Vlieghe E, Yombi JC, Liesenborghs L, Verhamme P, Meyfroidt G. Devos T, et al. Trials. 2020 Nov 27;21(1):981. doi: 10.1186/s13063-020-04876-0. Trials. 2020. PMID: 33246499 Free PMC article. Clinical Trial.

1. Devos, et al. A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial. Trials. 2020;21:981. doi: 10.1186/s13063-020-04876-0. - DOI - PMC - PubMed